Company: PTPI
Filing Date: 2025-03-07
Form Type: PRE 14A
Source: 0001104659-25-021794
Chunk: 5

Company: Petros Pharmaceuticals, Inc.
Filing Date: 2025-03-07
Form: PRE 14A
Chunk 5
---
='center'>i

Petros Pharmaceuticals, Inc.
1185 Avenue of the Americas, 3rd Floor
New York, NY 10036

PROXY STATEMENT FOR THE
PETROS PHARMACEUTICALS, INC.
2025 SPECIAL MEETING OF STOCKHOLDERS
TO BE HELD ON APRIL 10, 2025</div>

This Proxy Statement, along
with the Notice of Special Meeting of Stockholders, contains information about the 2025 Special Meeting of Petros Pharmaceuticals, Inc.,
including any adjournments or postponements thereof. We are holding the Special Meeting at 10 a.m. Eastern Time, on Thursday, April 10,
2025, in virtual format at www.virtualshareholdermeeting.com/PTPI2025SM.

In this Proxy Statement,
we refer to Petros Pharmaceuticals, Inc. as “Petros,” “the Company,” “we” and “us.”

This Proxy Statement relates
to the solicitation of proxies by our Board of Directors for use at the Special Meeting.

On or about [ ], 2025, we
began sending proxy materials to stockholders entitled to vote at the Special Meeting.

<div align='center'>IMPORTANT NOTICE REGARDING THE
AVAILABILITY OF PROXY MATERIALS FOR THE
STOCKHOLDER SPECIAL MEETING
TO BE HELD ON APRIL 10, 2025</div>

This Proxy Statement and
our Notice of Special Meeting of Stockholders are available for viewing, printing and downloading at www.proxyvote.com.

The executive offices of
the Company are located at, and the mailing address of the Company is, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036.

At the 2025 special meeting
of stockholders (the “Special Meeting”), the Company expects the following matters to be acted upon:

| 1. | the approval of, for purposes of complying with Nasdaq Listing Rule 5635(d),                                                            
 the issuance of shares of our common stock, par value $0.0001 per share (the “Common Stock”) underlying the Series A                    
 warrants (the “Series A Warrants”) and Series B warrants (the “Series B Warrants” and, together                                         
 with the Series A Warrants, the “Series Warrants”) issued by us in a public offering transaction on February 19,                        
 2025 (including shares of Common Stock issuable upon operation of certain anti-dilutions provisions applicable to such Series